AbbVie Inc. $ABBV Shares Acquired by Juncture Wealth Strategies LLC

Juncture Wealth Strategies LLC grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 451.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,559 shares of the company’s stock after acquiring an additional 7,824 shares during the quarter. Juncture Wealth Strategies LLC’s holdings in AbbVie were worth $2,500,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. State Street Corp grew its holdings in shares of AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after acquiring an additional 106,091 shares during the period. Franklin Resources Inc. boosted its position in AbbVie by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 14,881,504 shares of the company’s stock worth $3,400,274,000 after purchasing an additional 330,104 shares during the last quarter. Legal & General Group Plc purchased a new position in AbbVie in the second quarter worth $2,905,952,000. Finally, Deutsche Bank AG grew its stake in AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after purchasing an additional 1,241,587 shares during the period. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ABBV shares. Piper Sandler raised their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Sanford C. Bernstein reissued a “market perform” rating and issued a $225.00 target price (up from $203.00) on shares of AbbVie in a research report on Tuesday, June 23rd. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $296.00 price target (up from $278.00) on shares of AbbVie in a research report on Monday, August 3rd. Finally, HSBC increased their price target on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $273.82.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

AbbVie Trading Up 0.3%

Shares of ABBV stock traded up $0.89 during trading hours on Tuesday, hitting $266.65. 4,500,600 shares of the company’s stock were exchanged, compared to its average volume of 6,436,153. The company has a market capitalization of $471.11 billion, a PE ratio of 75.32, a PEG ratio of 1.19 and a beta of 0.24. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $269.39. The business’s 50 day simple moving average is $258.05 and its 200-day simple moving average is $235.01.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s payout ratio is presently 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong Phase 3 lymphoma results: AbbVie and Genmab reported that Epkinly (epcoritamab) combined with R-CHOP significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma. The combination reduced the risk of disease progression or death by 51% versus R-CHOP alone, potentially positioning Epkinly as a frontline treatment standard and creating a larger commercial opportunity. The companies plan to discuss the results with global regulators. AbbVie and Genmab Epkinly Phase 3 results
• Positive Sentiment: Analysts raise their outlook: Scotiabank lifted its ABBV price target from $280 to $320 and maintained a “sector outperform” rating. HSBC separately outlined a bullish case for a potential $315 target, citing AbbVie’s pipeline and growth prospects. Wall Street’s average recommendation remains equivalent to “Buy,” although analyst optimism is already reflected in the stock’s elevated valuation. Scotiabank raises AbbVie price target
• Positive Sentiment: Pipeline diversification: Coverage highlighted AbbVie’s newly approved Parkinson’s disease pill, described as the first FDA-approved selective D1/D5 therapy, adding another potential growth driver beyond immunology and oncology.
• Neutral Sentiment: Upcoming earnings catalyst: Investors are looking ahead to AbbVie’s third-quarter report, expected later this month. Results and management’s outlook will be important tests for the stock after its substantial rally.
• Negative Sentiment: Lower near-term EPS guidance: AbbVie incorporated $216 million of acquired in-process research and development and milestone expenses into its third-quarter outlook, reducing adjusted EPS guidance to $3.73–$3.77 from the prior range of $3.87–$3.91. Full-year adjusted EPS guidance was also reduced by $0.11 to $13.76–$13.96, creating a modest earnings headwind. AbbVie updates 2026 EPS guidance
• Negative Sentiment: Pricing uncertainty: AbbVie’s participation in a federal 340B rebate pilot ahead of 2027, together with an anticipated Medicare price reduction for Vraylar, could pressure future pricing and margins, though the near-term financial impact remains uncertain.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.